Hyderabad, Telengana -- (SBWire) -- 02/21/2023 --Market Dynamics:
The factors influencing the global paroxysmal nocturnal hemoglobinuria treatment market are the increasing research and development and the growing prevalence of paroxysmal nocturnal hemoglobinuria.
The increasing research and development are expected to drive the market growth in the forecast period
PNH (paroxysmal nocturnal hemoglobinuria) is an acquired (not inherited) disorder that causes the premature death of blood cells and impairs their production. The disorder affects red blood cells (erythrocytes), which transport oxygen, white blood cells (leukocytes), which fight infections, and platelets (thrombocytes), which help the body clot. PNH can strike anyone at any age, but it is mostly diagnosed in young adults.
PNH patients are more likely to develop blood-forming cells (leukemia) cancers. People who have or have been treated for aplastic anemia, a type of blood disease, may develop PNH in some cases. The signs and symptoms of PNH go away in a small percentage of people. PNH treatment used to be mostly supportive. Patients received a blood transfusion and iron supplementation for recurrent hemolysis and anemia. To prevent thrombosis, they were given anti-thrombosis prophylaxis.
Book Your Free Sample Copy of This Report: https://www.datamintelligence.com/download-sample/paroxysmal-nocturnal-hemoglobinuria-treatment-market
An allogeneic bone marrow transplant was offered for bone marrow complications. Eculizumab is a life-saving therapy that reduces the need for blood transfusions by more than half and reduces the risk of thrombotic events and serious vascular complications by nearly seventy percent. Eculizumab works by preventing factor C5 from working. Membrane attack complexes are formed by all complement pathways (MAC). C3b, C5b, and other complement factors combine to form MAC. Several new complement inhibitors are currently being tested in humans to treat PNH. Some of these new therapeutic agents block the 5th component of complement, similar to eculizumab/ravulizumab, while others inhibit complement at other sites.
Side effects associated with paroxysmal nocturnal hemoglobinuria medication are expected to hamper the market growth
Some of the side effects of eculizumab are the onset, duration, and severity of eculizumab side effects are frequently predictable. Eculizumab side effects are almost always reversible and disappear once treatment is finished. The side effects of eculizumab may be manageable. There are numerous ways to reduce or avoid the negative effects of eculizumab.
For patients taking eculizumab, the following side effects are common (occurring in more than 30% of cases) blood pressure problems, diarrhea, and headache.
COVID-19 Impact Analysis:
The coronavirus disease (COVID-19) pandemic has complicated cancer treatment. Important issues include balancing the risk of treatment delay versus COVID-19 harm, minimizing the negative effects of social distancing during care delivery, and allocating limited health care resources appropriately and fairly. COVID-19 infection results in an overactive complement system and an inflammatory response that worsens lung injury and has poor clinical outcomes. Because of the interaction between the complement system and COVID-19 infection, immunosuppression may be a viable option for reducing the effects of complement-mediated inflammatory destruction in COVID-19 infection. Furthermore, patients with PNH may be vulnerable to COVID-19 complications due to their compromised immune status. The therapeutic use of complement inhibitors may be an effective strategy to control systemic inflammation in COVID-19 infection based on this immunological rationale. Specific clinical and economically cost-effective therapeutic options should be explored and prioritized considering the worldwide COVID19 pandemic. In a patient with PNH, treatment with ravulizumab during COVID19 pneumonia was safe, cost-effective, and had a favorable clinical course. Hence, covid-19 is expected to have impacted the market growth.
Segment Analysis:
Stem Cell Transplant segment is expected to dominate the market growth
PNH patients can only be treated with allogeneic stem cell transplantation. Clinical results from various SCT programs show that this procedure is only appropriate for a small number of patients with similar rare disorders. Only severe cases of PNH with life-threatening complications such as transformation to leukemia or aplastic anemia should be treated with stem cell transplants. By eliminating the defective clone with conditioning intensity and/or the graft-versus-haematopoiesis effect and replacement with a donor haematopoietic system, logeneic HSCT remains a potentially curative option for PNH.
However, because of the high treatment-related mortality, HSCT for classical PNH is not recommended in countries where eculizumab is available, even though it is a therapeutic option for patients with PNH/BMF. Moreover, because eculizumab is unavailable in China, steroid and allogeneic HSCT are usually considered first-line therapy for classical PNH and PNH/BMF. In a randomized trial of patients with PNH, eculizumab treatment has never been directly compared to HSCT.
Geographical Analysis:
North America region is expected to hold the largest market share in the global paroxysmal nocturnal hemoglobinuria treatment market
The regional market is expected to grow due to the potential approval of promising pipeline drugs and the growing prevalence of paroxysmal nocturnal hemoglobinuria.
While epidemiologic data is limited, it is estimated that 5,000-6,000 people in the United States are affected by PNH. Moreover, on 21st December 2018, Ravulizumab, a long-acting complement inhibitor that prevents hemolysis, was approved by the US Food and Drug Administration (FDA) to treat adults with paroxysmal nocturnal hemoglobinuria (PNH). Hence, the increasing drug approvals in this region are expected to drive market growth.
Competitive Landscape:
With mergers, acquisitions, and product launches, the global paroxysmal nocturnal hemoglobinuria treatment market is moderately competitive. Some of the key players in the market are Alexion Pharmaceuticals, Inc., Akari Therapeutics, Plc, Novartis AG, Apellis Pharmaceuticals, Inc., Regeneron Pharmaceuticals.
Read Complete Report Summary and TOC: https://www.datamintelligence.com/research-report/paroxysmal-nocturnal-hemoglobinuria-treatment-market
About Us:
DataM Intelligence 4Market Research is a market intelligence platform that gives access to syndicated, customized reports and consulting to its clients in one place. As a firm with rich experience in research and consulting across multiple domains, we are a one-stop solution that will cater to clients needs in key business areas. DataM Intelligence has an online platform whose coverage includes industries such as chemicals and materials, agriculture, health care services, animal feed and food & beverages, among others. Our platform has Insights into markets that uncover the latest market research data distinct from the competition. With coverage across ten major industries in the marketplace research, DataM Intelligence benefits thousands of companies by helping them take their innovations early to the market by providing a complete view of the market with statistical forecasts. Our strategy-centric framework and value-added services will give individuals and corporates easy access and custom personalization to research and markets.
Paroxysmal Nocturnal Hemoglobinuria Treatment Market Is Poised to Cross at High CAGR of 11.4% in 2022-2029
Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Segmented By Treatment(Stem Cell Transplant, Blood Transfusion, Medication, Others), By End Users(Hospitals, Clinics, Other)